Who is sponsoring NCT04203264?

NCT04203264 is sponsored by Changhai Hospital.

What drugs are being tested in NCT04203264?

Interventions in NCT04203264: Real-time artificial intelligence identification system.

What condition does NCT04203264 study?

NCT04203264 studies Capsule Endoscopy.

Is NCT04203264 still recruiting?

NCT04203264 is currently status unknown. Last updated 18 December 2019.

Last reviewed 2019-12-18 · How we verify

NCT04203264

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Real-Time Identification System of Magnetically Controlled Capsule Endoscopy Using Artificial Intelligence

Status unknown Last updated 18 December 2019

What this trial tests

trial testing Real-time artificial intelligence identification system in Capsule Endoscopy in 50 participants. Status unknown.

Timeline

16 December 2019

Primary endpoint
1 January 2020

1 January 2020

Quick facts

Lead sponsor	Changhai Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	16 December 2019
Primary completion	1 January 2020
Estimated completion	1 January 2020
Sites	1 location across China

Drugs / interventions tested

Real-time artificial intelligence identification system

Conditions studied

Capsule Endoscopy — all drugs for Capsule Endoscopy →

Sponsor

Changhai Hospital

Who can join

Adults 18 to 80, any sex, with Capsule Endoscopy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the performance of real-time auxiliary system based on artificial intelligence algorithm in lesion detection and quality control in magnetically controlled capsule endoscopy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Capsule Endoscopy

Currently open trials in the same condition.

NCT07325344 — Active Locomotion of Magnetically Controlled Capsule Endoscopy in the Small Bowel: A Feasibility Study · NA · recruiting

Other Changhai Hospital trials

Trials by the same sponsor.

NCT07490002 — Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC · Phase 2 · not yet recruiting
NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
NCT07507071 — Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions · not yet recruiting
NCT07481591 — Capsule Endoscopy in GI Bleeding: A Retrospective Study · not yet recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04203264 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Changhai Hospital
Last refreshed: 18 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04203264.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing